HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation

Soomin Ahn; Ji Won Woo; Kyoungyul Lee; So Yeon Park

doi:10.4132/jptm.2019.11.03

Journal List > J Pathol Transl Med > v.54(1) > 1152433

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Ahn, Woo, Lee, and Park: HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation

Review

J Pathol Transl Med 2020;54(1):34-44.

Published online: 6 November 2019

DOI: https://doi.org/10.4132/jptm.2019.11.03

HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation

Soomin Ahn¹

, Ji Won Woo^1,²

, Kyoungyul Lee³

, So Yeon Park^1,²

¹Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea

²Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

³Department of Pathology, Kangwon National University Hospital, Chuncheon, Korea

Corresponding Author: So Yeon Park, MD, PhD, Department of Pathology, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea Tel: +82-31-787-7712, Fax: +82-31-787-4012, E-mail: sypmd@snu.ac.kr

Received 9 October 2019 Accepted 3 November 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed breast cancer in pathology. Currently, HER2 immunohistochemistry (IHC) is used for a screening test, and in situ hybridization is used as a confirmation test for HER2 IHC equivocal cases. Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer. During HER2 interpretation, some pitfalls such as intratumoral HER2 heterogeneity and increase in chromosome enumeration probe 17 signals may lead to inaccurate assessment of HER2 status. Moreover, HER2 status can be altered after neoadjuvant chemotherapy or during metastatic progression, due to biologic or methodologic issues. This review addresses recent updates of ASCO/CAP guidelines and factors complicating in the interpretation of HER2 status in breast cancers.

Keywords: Breast cancer, HER2, ASCO/CAP guidelines, HER2 heterogeneity, CEP17 copy number gain

Human epidermal growth factor receptor 2 (HER2) is a protooncogene that encodes epidermal growth factor receptor with tyrosine kinase activity, located on chromosome 17 at q21. In breast cancers, HER2 gene is amplified in 15%–20% of invasive breast cancers and its amplification is closely linked to HER2 protein overexpression [1,2]. HER2 amplification is a poor prognostic factor associated with a high rate of recurrence and mortality, and is a predictive factor for response to anthracycline-based chemotherapies in patients with breast cancer [1,2]. Most importantly, it is a sole predictive marker for treatment benefits from HER2-targeting agents such as trastuzumab, lapatinib, and pertuzumab. As HER2-targeted therapy is exclusively effective in HER2-overexpressed and/or HER2-amplified breast cancers, precise assessment of HER2 status is an essential step for treatment of breast cancer. In this review, we focused on changes in the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 interpretation and some pitfalls in the interpretation of HER2 status in breast cancers.

METHODS OF HER2 TESTING

Currently, immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and chromogenic in situ hybridization (CISH) including silver in situ hybridization (SISH) are regarded as standard methods for determination of HER2 status in breast cancer, and some of them have been approved by the U.S. Food and Drug Administration (FDA) for HER2 testing in breast cancer since 1998.

Although HER2 status can be directly tested by in situ hybridization (ISH), many laboratories have adopted IHC as a screening test, and FISH as a confirmation test for HER2 IHC equivocal cases, considering higher failure rate, longer procedure time and higher reagent cost of FISH, compared to that of IHC. Moreover, high concordance has been found between HER2 protein overexpression by IHC and gene amplification by FISH [3-5]. Finally, the 2007 ASCO/CAP guidelines stated that HER2 status should be initially assessed by IHC using a semi-quantitative scoring system (Fig. 1), and confirmed by FISH in all IHC score 2+ equivocal cases [6].

Bright-field in situ hybridization such as CISH and SISH has advantage in that it allows histologic evaluation of tumors, utilizes ordinary microscope, leaves permanent signals for archival storage, and can be fully automated [7]. Moreover, it shows more than 95% concordance rate with FISH [8-11]. Thus, CISH and SISH are now admitted as an alternative to FISH.

CHANGES IN GUIDELINES ON INTERPRETATION OF HER2 STATUS

For uniformity in accuracy and reproducibility of HER2 testing in breast cancer, ASCO/CAP jointly released guidelines and recommendations for HER2 testing first in 2007, addressing a wide range of pre-analytic, analytic and post-analytic variables [6]. This guideline focused on limiting the false-positive results, adopting a higher cutoff of 30% for HER2 IHC positivity (3+), instead of 10% cutoff previously recommended by FDA (Table 1). For FISH analysis, HER2 gene was regarded as amplified if HER2/chromosome enumeration probe 17 (CEP17) ratio >2.2 for dual-probe assay (instead of the previously recommended ratio of 2.0) or HER2 gene copy >6 signals per cell for single-probe assay.

After then, the revised 2013 ASCO/CAP guideline focused on maximizing identification of patients who can benefit from HER2-targeted therapy and minimizing false-negative results [12]. The range of HER2 IHC equivocal cases (2+) was widened, and HER2 IHC 3+ was defined using 10% as cutoff value, not using 30% (Table 1). When using validated dual-probe ISH assay, HER2/CEP17 ratio ≥2.0 or HER2/CEP17 ratio <2.0 and average HER2 copy number ≥6.0 was regarded as ISH positive (Table 2). The 2007 and 2013 ASCO/CAP guidelines included ISH equivocal results, which had been a problem for clinical decision making.

Since the publication of the 2013 guideline, several laboratories and clinical investigators have reported on the practical implications of the 2013 guidelines and increased frequencies of equivocal results [13]. The HER2 testing Expert Panel wished to clarify controversial issues in the 2013 guideline, and in that context the 2018 updated ASCO/CAP guidelines on HER2 testing was reported [13]. The updated guideline addressed five clinical questions. The first question was about the definition of HER2 IHC 2+, and it was revised as weak to moderate complete membrane staining observed in >10% of tumor cells. The second question was about repeated HER2 test of initially negative case, and it was recommended that if the initial HER2 testing result in a core needle biopsy specimen is negative, a new HER2 test may (not ‘‘must’’) be ordered on the excision specimen based on specific clinical criteria. These two clinical questions were addressed in a previous correspondence by the Expert Panel [14]. The remaining three questions were about less common ISH patterns, and the updated HER2 testing algorithm addressed the workup for these three clinical scenarios, occasionally found when using a dual-probe ISH assay. These scenarios were described as ISH group 2 (HER2/CEP17 ratio ≥2.0; average HER2 copy number < 4.0 signals per cell), ISH group 3 (HER2/CEP17 ratio <2.0; average HER2 copy number ≥6.0 signals per cell), and ISH group 4 (HER2/CEP17 ratio <2.0; average HER2 copy number ≥ 4.0 and <6.0 signals per cell) [13]. The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to achieve the most accurate determination of HER2 status based on combined interpretation of the ISH and IHC assay [13]. It was recommended that laboratories using single-probe ISH assays include concomitant IHC review as part of the interpretation of all ISH assay results [13]. By this approach, the HER2 status was designated to positive or negative with no equivocal category.

Although complicated, HER2 status is basically determined by IHC results in the dual-probe ISH groups 2 to 4. While cases with HER2 IHC 3+ are regarded as HER2 positive, those with HER2 IHC 0 or 1+ are regarded as HER2 negative. In cases with HER2 IHC 2+, an additional observer blinded to previous result recounts ISH. As for ISH groups 2 and 4, if the repeated ISH result is designated to the same ISH group, it is finally regarded as HER2 negative. On the contrary, as for ISH group 3, if the repeated ISH result is categorized to the same group, it is finally regarded as HER2 positive. If the repeated ISH shows other ISH result, the results should be adjudicated per internal procedures to determine final category. The changes on HER2 interpretation in the updated 2018 ASCO/CAP guidelines in comparison with previous 2007 and 2013 guidelines are summarized in Tables 1 and 2.

Recent studies on implementation of the updated 2018 ASCO/CAP guidelines have shown significant increases of HER2 negative rates through reclassification of ISH equivocal cases by the 2013 guidelines [15-17]. The updated guidelines seem to provide much clearer instructions for HER2 status designation by using concomitant IHC review in ISH groups 2, 3 and 4, and eliminating ISH equivocal category [15].

COMPLICATING FACTORS FOR HER2 INTERPRETATION

Intratumoral HER2 heterogeneity

HER2 status has been thought to be fairly homogeneous within a tumor. However, intratumoral heterogeneity of HER2 gene amplification, that is, intratumoral HER2 heterogeneity, is found in a subset of breast cancers. It has important clinical implications, in that it can contribute to inaccurate assessment of HER2 status and affect treatment responses to HER2-targeted therapy [18]. In previous studies, our group has shown that intratumoral HER2 heterogeneity is more common in breast cancer with equivocal HER2 protein expression and low-grade HER2 gene amplification [19,20]. Intratumoral HER2 heterogeneity was associated with poor clinical outcome in patients with HER2-positive primary breast cancer [19]. Moreover, it was related to poor response to trastuzumab and decreased survival in patients with HER2-positive metastatic breast cancer [20]. In a subsequent study, Lee et al. [21] reported that cases with HER2 regional heterogeneity showed a decreased disease-free survival rate compared to those without heterogeneity in the hormone receptor-positive subgroup of breast cancer patients treated with adjuvant trastuzumab. In a neoadjuvant setting, intratumoral HER2 heterogeneity was also found to be associated with incomplete response to anti-HER2 chemotherapy [22].

The CAP addressed this issue and published a separate recommendation in 2009 and defined HER2 genetic heterogeneity as the presence of tumor cells with HER2/CEP17 signal ratios greater than 2.2 in 5% to 50% of the tumor cells tested [23]. However, this recommendation has some problems, in that it was based on expert opinion rather than evidence, and artificial heterogeneity caused by technical issues could be regarded as HER2 genetic heterogeneity. Finally, the 2013 ASCO/CAP guidelines added a recommendation about HER2 heterogeneity for HER2 ISH interpretation, stating that if there is a second population of cells with increased HER2 signals/cell and this cell population is more than 10% of tumor cells on the slide, a separate counting of at least 20 non-overlapping cells must also be performed within this cell population and reported [12].

HER2 heterogeneity can be found as distinct clusters of amplified cells among non-amplified cells or appear as intermixed amplified and non-amplified cells (Fig. 2). Basically, it is important to scan all fields when observing ISH slide and to match it with HER2 IHC slide to detect areas with HER2 heterogeneity. From this point of view, CISH or SISH has an advantage in evaluating HER2 heterogeneity, because it can be easily matched with HER2 IHC slide under light microscope. The HER2/CEP17 ratios or HER2 copy number should be calculated separately for amplified and non-amplified areas. Suggestions for how to assess intratumoral HER2 heterogeneity are summarized in Table 3 [24,25].

CEP17 copy number gain

CEP17 copy number gain is a genetic change commonly observed during dual-probe HER2 ISH for breast cancer, with reported frequency of 3% to 46% in breast cancers [26]. In our study using 945 cases of invasive breast cancer, CEP17 copy number gain was observed in 29.9% when using the definition of CEP17 copy number gain as mean CEP17 ≥2.6, and was found in 19.7% with the definition of CEP17 copy number gain as CEP17 ≥3.0 [27]. This had been thought to result from increasing numbers of whole chromosome 17, which is referred to as polysomy 17. However, subsequent studies have revealed that true polysomy 17 is a rare phenomenon in breast cancers, and CEP17 copy number gain results from amplification or copy number gain in the centromeric or pericentromeric region [28-32].

Although it is still controversial, CEP17 copy number gain has been found to be associated with increased HER2 protein expression [27,33-35]. However, CEP17 copy number gain without HER2 gene amplification was not associated with benefit from HER2-targeted therapy in breast cancers [36,37]. Moreover, CEP17 copy number gain in breast cancers has been reported to be associated with adverse clinicopathological features [27,38-40] and response to anthracycline-based therapy in breast cancer [41,42]. However, as for its prognostic significance, there have been conflicting results [43-46]. Recently, our group has shown that CEP17 copy number gain is an independent poor prognostic factor in patients with luminal/HER2-negative breast cancers, suggesting that CEP17 copy number gain may reflect chromosomal instability in breast cancer [27].

CEP17 copy number gain may affect the interpretation of HER2 ISH, and lead to an underestimation of HER2 status. Therefore, the 2013 ASCO/CAP guideline recommended to repeat HER2 testing using an alternative probe for CEP17 or for another gene in chromosome 17 not expected to co-amplify with HER2 for the ISH equivocal cases (now ISH group 4 in the updated 2018 ASCO/CAP guideline) [12,26]. However, following studies have shown that with alternative probes, HER2 ISH equivocal cases were upgraded to HER2 ISH positive status in a significant proportion, and clinicopathologic features of those upgraded cases were not compatible with those of HER2-amplified breast cancers, suggesting that use of alternative probe is not reliable in clinical practice [32,47]. The updated 2018 ASCO/CAP guidelines do not recommend the use of alternative probe as standard practice due to limited evidence on its analytical and clinical validity [13].

Changes in HER2 status after neoadjuvant chemotherapy

Neoadjuvant chemotherapy (NAC) is currently considered as standard treatment for locally advanced breast cancer [48]. Alteration of biomarker status after NAC is occasionally found in breast cancer [49,50]. Hormone receptor status changed more often than HER2 status, and as for hormone receptors, positive to negative conversion was more common than negative to positive conversion [51,52]. The frequency of HER2 change after NAC is reported in up to 15%, and both positive to negative conversion and negative to positive conversion were found with no preponderance [52-66]. Previous studies on HER2 change after NAC are summarized in Table 4. In our study, HER2 status was altered after NAC in 3.4% with positive to negative conversion in 0.9% and negative to positive conversion in 2.5% [52]. Most cases with negative to positive conversion of HER2 status after NAC showed low level of HER2 amplification, and the HER2/CEP17 ratio ranged from 2.2 to 4.4 (data not shown in a previous study) [52]. Cockburn et al. [61] also reported the mean HER2/CEP17 ratio in resection specimens with HER2 positive conversion was 3.7. Although there are no guidelines about whether treatment should be modified based on altered biomarker status after NAC, the change of HER2 status may have an impact on the therapeutic management in certain patients. Accordingly, re-evaluation of biomarkers including HER2 after NAC is recommended for proper management.

The mechanism of HER2 conversion after NAC is not well understood. This can be partly explained by the selection of HER2-positive or HER2-negative clones after NAC, tumor heterogeneity, and pre-analytical and analytical pitfalls, Guarneri et al. [67] evaluated HER2 status change on 107 HER2-positive patients treated with NAC with or without anti-HER2 agents. They reported that patients with tumors undergoing HER2 negative conversion following treatment had significantly reduced disease-free survival compared to patients with maintained HER2 positivity [67]. However, the prognostic significance of HER2 status change is still unclear.

Finally, caution is needed in interpretation of HER2 ISH after NAC in distinguishing between a true HER2 amplification and increase of HER2 copy number by chromosome 17 polysomy [68]. Increase in HER2 copy number could not be attributed to true HER2 amplifications, but instead could reflect polyploidization after chemotherapy, which presumably affects all chromosomes [68]. Careful evaluation using dual-probe ISH with concomitant IHC review is recommended.

Change in HER2 status with metastatic progression

Change in receptor status during metastatic progression, a phenomenon called “receptor conversion” occurs not only in hormonal receptors, but also in HER2. The reported frequency of HER2 conversion varies a lot between studies, but it is usually observed less often than hormone receptor conversion. Schrijver et al. [69] reported in their meta-analysis that pooled frequency of HER2 positive to negative conversion was 21.3%, and that of negative to positive conversion was 9.5%. Previous studies on HER2 change during metastatic progression are summarized in Table 5 [70-79]. In our study, HER2 receptor status changed in 12 out of 152 cases (7.9%) during metastatic progression: nine cases (5.9%) were negative conversion, and three cases (2.0%) were positive conversion [79].

Similar to HER2 status alteration after NAC, little is known about the true mechanism of HER2 status conversion during metastatic progression. It would be reasonable to postulate intratumoral heterogeneity and selection pressure from treatment play a role in HER2 status conversion. In our study, cases with positive to negative conversion showed significantly lower level of HER2 protein expression and heterogeneous HER2 gene amplification, compared to consistently positive cases [79]. From this observation, it can be inferred that tumors with HER2 heterogeneity have a propensity to show different status in metastatic sites, because HER2-targeted therapy drives susceptible clones to fade away.

HER2 conversion is not a common event, but it is important to discover it because of its relation with treatment. There are some studies which reported response to trastuzumab treatment in patients who gained HER2 positivity in metastatic lesions [77,80]. For this reason, it is now widely recommended to reevaluate receptor status including HER2 in metastatic lesions, if possible [13,81].

CONCLUSION

The ASCO/CAP guidelines on HER2 interpretation in breast cancer, which were released first in 2007 and subsequently updated in 2013 and 2018, have been changing to provide much clearer instructions for HER2 status designation. The updated 2018 ASCO/CAP guideline focused on three dual-probe ISH groups (groups 2, 3, and 4) with less common ISH patterns, and recommended concomitant IHC review for these ISH groups to achieve the most accurate determination of HER2 status. Finally, in the updated 2018 ASCO/CAP guideline, HER2 status, as determined by ISH, is categorized to positive or negative with no equivocal results.

There are some complicating factors for HER2 interpretation including HER2 heterogeneity, CEP17 copy number gain, and HER2 status alteration after NAC or during metastatic progression. It is important to scan the entire ISH slide and to match it with HER2 IHC to detect HER2 heterogeneity. Separate counting should be performed in both amplified and non-amplified areas. CEP17 copy number gain may lead to an underestimation of HER2 status, but the use of alternative probe is not recommended in the updated 2018 ASCO/CAP guidelines due to the limited evidence on its analytical and clinical validity. HER2 conversion is occasionally found after NAC or during metastasis progression. The change of HER2 status may have an impact on the therapeutic decision and response to treatment. Accordingly, re-evaluation of HER2 status should be performed in postNAC specimens and metastatic lesions.

Notes

Author contributions

Project administration: SA.

Supervision: SYP.

Writing—original draft: SA, JWW, KL, SYP.

Writing—review & editing: SYP.

Conflicts of Interest

S.Y.P. is the editor-in-chief of the Journal of Pathology and Translational Medicine and was not involved in the editorial evaluation or decision to publish this article. All remaining authors declare that they have no potential conflicts of interest.

Funding

No funding to declare.

REFERENCES

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235:177–82.

2. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989; 7:1120–8.

3. Couturier J, Vincent-Salomon A, Nicolas A, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol. 2000; 13:1238–43.

4. Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001; 19:354–63.

5. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004; 291:1972–7.

6. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25:118–45.

7. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000; 157:1467–72.

8. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002; 82:1007–14.

9. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol. 2005; 18:1015–21.

10. Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007; 451:19–25.

11. Koh YW, Lee HJ, Lee JW, Kang J, Gong G. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod Pathol. 2011; 24:794–800.

12. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31:3997–4013.

13. Wolff AC, Hammond ME, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018; 36:2105–22.

14. Wolff AC, Hammond ME, Hicks DG, et al. Reply to E.A. Rakha et al. J Clin Oncol. 2015; 33:1302–4.

15. Liu ZH, Wang K, Lin DY, et al. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 FISH results of 2233 cases. Breast Cancer Res Treat. 2019; 175:51–7.

16. Gordian-Arroyo AM, Zynger DL, Tozbikian GH. Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update. Am J Clin Pathol. 2019; 152:17–26.

17. Xu B, Shen J, Guo W, Zhao W, Zhuang Y, Wang L. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer. Pathol Res Pract. 2019; 215:251–5.

18. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol. 2007; 25:5418–25.

19. Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 2012; 25:938–48.

20. Lee HJ, Seo AN, Kim EJ, et al. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. Am J Clin Pathol. 2014; 142:755–66.

21. Lee HJ, Kim JY, Park SY, et al. Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2- positive breast cancer patients treated with adjuvant trastuzumab. Am J Clin Pathol. 2015; 144:570–8.

22. Hou Y, Nitta H, Wei L, et al. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Res Treat. 2017; 166:447–57.

23. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009; 133:611–2.

24. Walker RA, Bartlett JM, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008; 61:818–24.

25. Starczynski J, Atkey N, Connelly Y, et al. HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol. 2012; 137:595–605.

26. Hanna WM, Ruschoff J, Bilous M, et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2014; 27:4–18.

27. Lee K, Jang MH, Chung YR, et al. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype. Hum Pathol. 2017; 61:111–20.

28. Gunn S, Yeh IT, Lytvak I, et al. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer. 2010; 10:396.

29. Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 2009; 22:1169–75.

30. Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat. 2010; 120:1–7.

31. Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009; 219:16–24.

32. Jang MH, Kim EJ, Kim HJ, Chung YR, Park SY. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number. Breast Cancer Res Treat. 2015; 153:67–77.

33. Ma Y, Lespagnard L, Durbecq V, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res. 2005; 11:4393–9.

34. Merola R, Mottolese M, Orlandi G, et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer. 2006; 42:1501–6.

35. Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol. 2008; 61:317–21.

36. Downey L, Livingston RB, Koehler M, et al. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res. 2010; 16:1281–8.

37. Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010; 28:4307–15.

38. Orsaria M, Khelifa S, Buza N, Kamath A, Hui P. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification. J Clin Pathol. 2013; 66:1070–5.

39. Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol. 2009; 22:1044–8.

40. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008; 26:4869–74.

41. Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010; 11:266–74.

42. Tibau A, Lopez-Vilaro L, Perez-Olabarria M, et al. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. Neoplasia. 2014; 16:861–7.

43. Kim A, Shin HC, Bae YK, et al. Multiplication of chromosome 17 centromere is associated with prognosis in patients with invasive breast cancers exhibiting normal HER2 and TOP2A status. J Breast Cancer. 2012; 15:24–33.

44. Nielsen KV, Ejlertsen B, Moller S, et al. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. Mol Oncol. 2012; 6:88–97.

45. Zaczek A, Markiewicz A, Supernat A, et al. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer. Pathol Oncol Res. 2012; 18:885–94.

46. Fountzilas G, Dafni U, Bobos M, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer. 2013; 13:163.

47. Sneige N, Hess KR, Multani AS, Gong Y, Ibrahim NK. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: a cohort study. Cancer. 2017; 123:1115–23.

48. Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012; 23 Suppl 10:x231–6.

49. Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg. 2003; 186:348–50.

50. Makris A, Powles TJ, Allred DC, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat. 1999; 53:51–9.

51. Zhang N, Moran MS, Huo Q, Haffty BG, Yang Q. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest. 2011; 29:594–8.

52. Ahn S, Kim HJ, Kim M, et al. Negative conversion of progesterone receptor status after primary systemic therapy is associated with poor clinical outcome in patients with breast cancer. Cancer Res Treat. 2018; 50:1418–32.

53. De La Cruz LM, Harhay MO, Zhang P, Ugras S. Impact of neoadjuvant chemotherapy on breast cancer subtype: does subtype change and, if so, how?: IHC profile and neoadjuvant chemotherapy. Ann Surg Oncol. 2018; 25:3535–40.

54. Xian Z, Quinones AK, Tozbikian G, Zynger DL. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management? Hum Pathol. 2017; 62:215–21.

55. Reddy OL, Apple SK. Breast cancer biomarker changes after neoadjuvant chemotherapy: a single institution experience and literature review. Clin Oncol. 2017; 2:1245.

56. Gahlaut R, Bennett A, Fatayer H, et al. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression: implications for the practising oncologist. Eur J Cancer. 2016; 60:40–8.

57. Lim SK, Lee MH, Park IH, et al. Impact of molecular subtype conversion of breast cancers after neoadjuvant chemotherapy on clinical outcome. Cancer Res Treat. 2016; 48:133–41.

58. Zhou X, Zhang J, Yun H, et al. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. Oncotarget. 2015; 6:36894–902.

59. Jin X, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. Oncotarget. 2015; 6:9600–11.

60. Yang YF, Liao YY, Li LQ, Xie SR, Xie YF, Peng NF. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer. Pathol Res Pract. 2013; 209:797–802.

61. Cockburn A, Yan J, Rahardja D, et al. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. Hum Pathol. 2014; 45:249–58.

62. Lee HC, Ko H, Seol H, et al. Expression of immunohistochemical markers before and after neoadjuvant chemotherapy in breast carcinoma, and their use as predictors of response. J Breast Cancer. 2013; 16:395–403.

63. Hirata T, Shimizu C, Yonemori K, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer. 2009; 101:1529–36.

64. Kasami M, Uematsu T, Honda M, et al. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast. 2008; 17:523–7.

65. Neubauer H, Gall C, Vogel U, et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res. 2008; 28:1797–804.

66. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003; 88:406–12.

67. Guarneri V, Dieci MV, Barbieri E, et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol. 2013; 24:2990–4.

68. Valent A, Penault-Llorca F, Cayre A, Kroemer G. Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management. Cancer Genet. 2013; 206:37–41.

69. Schrijver W, Suijkerbuijk KP, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst. 2018; 110:568–80.

70. de Duenas EM, Hernandez AL, Zotano AG, et al. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. Breast Cancer Res Treat. 2014; 143:507–15.

71. Curtit E, Nerich V, Mansi L, et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist. 2013; 18:667–74.

72. Nakamura R, Yamamoto N, Onai Y, Watanabe Y, Kawana H, Miyazaki M. Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients. Breast Cancer. 2013; 20:336–41.

73. Aurilio G, Monfardini L, Rizzo S, et al. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol. 2013; 52:1649–56.

74. Duchnowska R, Dziadziuszko R, Trojanowski T, et al. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res. 2012; 14:R119.

75. Jensen JD, Knoop A, Ewertz M, Laenkholm AV. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat. 2012; 132:511–21.

76. Bogina G, Bortesi L, Marconi M, et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch. 2011; 459:1–10.

77. Chang HJ, Han SW, Oh DY, et al. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol. 2011; 41:593–9.

78. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010; 12:R75.

79. Woo JW, Chung YR, Ahn S, et al. Changes in biomarker status in metastatic breast cancer and their prognostic value. J Breast Cancer. 2019; 22:439–52.

80. Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res. 2011; 17:2055–64.

81. Van Poznak C, Harris LN, Somerfield MR. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Oncol Pract. 2015; 11:514–6.

Fig. 1.

Representative examples of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) in breast cancer. (A) HER2 IHC negative (0). (B) HER2 IHC negative (1+). (C) HER2 IHC equivocal (2+). (D) HER2 IHC positive (3+).

Fig. 2.

A representative breast cancer with intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity. (A) HER2 immunohistochemistry shows heterogeneous expression with strong, complete membranous expression on the right, and weak to moderate, incomplete membranous expression on the left. (B) HER2 silver in situ hybridization reveals high-level amplification on the right and no amplification on the left (inset, area of high-level amplification).

Table 1.

Changes in the ASCO/CAP guidelines: interpretation of HER2 immunohistochemistry

HER2 IHC status	2007 ASCO/CAP guidelines	2013 ASCO/CAP guidelines	2018 ASCO/CAP guidelines
Positive (3+)	Uniform intense membrane staining of >30% of invasive tumor cells	Circumferential membrane staining that is complete, intense, and in >10% of tumor cells	Circumferential membrane staining that is complete, intense, and in >10% of tumor cells
Equivocal (2+)	Complete membrane staining that is either non-uniform or weak in intensity but with obvious circumferential distribution in at least 10% of cells	Circumferential membrane staining that is incomplete and/or weak to moderate and within >10% of the invasive tumor cells	Weak to moderate complete membrane staining observed in >10% of tumor cells^a
Equivocal (2+)		Complete and circumferential membrane staining that is intense and within ≤10% of the invasive tumor cells
Negative (1+)	Weak incomplete membrane staining in any proportion of tumor cells	Incomplete membrane staining that is faint or barely perceptible and within >10% of the invasive tumor cells	Incomplete membrane staining that is faint or barely perceptible and within >10% of the invasive tumor cells
Negative (1+)	Weak, complete membrane staining in <10% of tumor cells
Negative (0)	No staining	No staining observed	No staining observed
Negative (0)	No staining	Incomplete membrane staining that is faint or barely perceptible and within ≤10% of the invasive tumor cells	Incomplete membrane staining that is faint or barely perceptible and within ≤10% of the invasive tumor cells

ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.

^a Unusual staining patterns of HER2 by IHC can be encountered that are not covered by these definitions. As one example, some specific subtypes of breast cancers can show IHC staining that is moderate to intense but incomplete (basolateral or lateral) and can be found to be HER2 amplified. Another example is circumferential membrane staining that is intense but in ≤ 10% tumor cells. Such cases can be considered equivocal (2+).

Table 2.

Changes in the ASCO/CAP guidelines: interpretation of HER2 status using dual-probe in situ hybridization assay

HER2 ISH status	2007 ASCO/CAP guidelines	2013 ASCO/CAP guidelines	2018 ASCO/CAP guidelines
ISH positive	HER2/CEP17 ratio > 2.2	HER2/CEP17 ratio ≥ 2.0	HER2/CEP17 ratio ≥ 2.0 and average HER2 copy number ≥ 4.0 (group 1)
		HER2/CEP17 ratio < 2.0 and average HER2 copy number ≥ 6.0	HER2/CEP17 ratio ≥ 2.0 and average HER2 copy number < 4.0 (group 2) with concurrent IHC 3+
			HER2/CEP17 ratio < 2.0 and average HER2 copy number ≥ 6.0 (group 3) with concurrent IHC 2+^a
			HER2/CEP17 ratio < 2.0 and average HER2 copy number ≥ 6.0 (group 3) with concurrent IHC 3+
			HER2/CEP17 ratio < 2.0 with average HER2 copy number ≥ 4.0 and < 6.0 (group 4) with concurrent IHC 3+
ISH equivocal	HER2/CEP17 ratio of 1.8-2.2	HER2/CEP17 ratio < 2.0 with average HER2 copy number ≥ 4.0 and < 6.0	(no equivocal category)
ISH negative	HER2/CEP17 ratio of < 1.8	HER2/CEP17 ratio < 2.0 with average HER2 copy number < 4.0	HER2/CEP17 ratio < 2.0 with average HER2 copy number < 4.0 (group 5)
			HER2/CEP17 ratio ≥ 2.0 and average HER2 copy number < 4.0 (group 2) with concurrent IHC 2+^b
			HER2/CEP17 ratio < 2.0 with average HER2 copy number ≥ 4.0 and < 6.0 (group 4) with concurrent IHC 2+^b
			Groups 2, 3, and 4 with concurrent IHC 0 or 1 +

ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; HER2, human epidermal growth factor receptor 2; ISH, in situ hybridization; CEP17, chromosome enumeration probe 17; IHC, immunohistochemistry.

^a An additional observer blinded to previous result recounts ISH. If the repeated ISH result is categorized to the same group, it is finally regarded as HER2 positive;

^b An additional observer blinded to previous result recounts ISH. If the repeated ISH result is designated to same ISH group, it is finally regarded as HER2 negative.

Table 3.

Assessment of HER2 heterogeneity in breast cancer

Suggestions
The pathologist should scan entire HER2 ISH slide before counting.
Review of HER2 IHC slide is helpful to find areas with potential HER2 amplification
From this point of view, CISH or SISH has an advantage to evaluate HER2 heterogeneity, because it can be easily matched with HER2 IHC slide under light microscope.
If there is a subpopulation of tumor cells with HER2 amplification comprising > 10% of tumor cells on the slide, a separate counting should be performed within the subpopulation.
The HER2/CEP17 ratios or HER2 gene copy number should be calculated for both amplified and non-amplified areas separately.
If possible, it is recommended that in situ hybridization report includes proportion of amplified cells within a tumor.

HER2, human epidermal growth factor receptor 2; ISH, in situ hybridization; IHC, immunohistochemistry; CISH, chromogenic in situ hybridization; SISH, silver in situ hybridization; CEP17, chromosome enumeration probe 17.

Table 4.

Summary of the previous studies on HER2 status alteration after neoadjuvant chemotherapy

Year	Author	Total No. of cases	Method	Frequency of HER2 alteration, n (%)
Year	Author	Total No. of cases	Method	Total	+ to –	– to +
2018	De La Cruz et al. [53]	54	IHC/FISH	2/54 (3.7)	1/54 (1.9)	1/54 (1.9)
2018	Ahn et al. [52]	442	IHC/SISH	15/442 (3.4)	4/442 (0.9)	11/442 (2.5)
2017	Xian et al. [54]	77	IHC/FISH	6/77 (7.8)	5/77 (6.5)	1/77 (1.3)
2017	Reddy et al. [55]	140	IHC/FISH	8/97 (8.2)	5/97 (5.2)	3/97 (3.1)
2016	Gahlaut et al. [56]	133	IHC/FISH	8/133 (6.0)	5/133 (3.8)	3/133 (2.3)
2016	Lim et al. [57]	290	IHC/FISH	17/290 (5.9)	17/290 (5.9)	0/290 (0)
2016	Zhou et al. [58]	107	IHC/FISH	5/107 (4.7)	3/107 (2.8)	2/107 (1.9)
2015	Jin et al. [59]	423	IHC/FISH	40/423 (9.5)	27/423 (6.4)	13/423 (3.1)
2013	Yang et al. [60]	113	IHC	17/113 (15.0)	9/113 (8.0)	8/113 (7.1)
2013	Cockburn et al. [61]	133	IHC/FISH	16/133 (12.0)	9/133 (6.8)	7/133 (5.3)
2013	Lee et al. [62]	120	IHC/FISH	11/107 (10.3)	6/107 (5.6)	5/107 (4.7)
2009	Hirata et al. [63]	368	IHC/FISH	35/368 (9.5)	22/368 (6.0)	13/368 (3.5)
2008	Kasami et al. [64]	173	IHC/FISH	0/173 (0)	0/173 (0)	0/173 (0)
2006	Neubauer et al. [65]	87	IHC	13/87 (14.9)	11/87 (12.6)	2/87 (2.3)
2003	Faneyte et al. [66]	50	IHC	3/50 (6.0)	2/50 (4.0)	1/50 (2.0)

HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; SISH, silver in situ hybridization.

Table 5.

Summary of the previous studies on HER2 status alteration during metastatic progression

Year	Author	Total No. of cases	Method	Site	Frequency of HER2 alteration, n (%)
Year	Author	Total No. of cases	Method	Site	Total	+ to –	– to +
2019	Woo et al. [79]	152	IHC/SISH	All	12/152 (7.9)	9/152 (5.9)	3/152 (2.0)
2014	de Duenas et al. [70]	165	IHC/FISH	All	5/165 (3.0)	0/165 (0.0)	5/165 (3.0)
2013	Curtit et al. [71]	219	IHC/FISH	All	8/219 (3.7)	6/219 (2.7)	2/219 (0.9)
2013	Nakamura et al. [72]	156	IHC/FISH	All	13/156 (8.3)	5/156 (3.2)	8/156 (5.1)
2013	Aurilio et al. [73]	86	IHC/FISH	Bone	6/86 (7.0)	2/86 (2.3)	4/86 (4.7)
2012	Duchnowska et al. [74]	119	IHC/FISH	Brain	17/119 (14.3)	7/119 (5.9)	10/119 (8.4)
2012	Jensen et al. [75]	114	IHC/FISH	All	10/114 (8.8)	2/114 (1.8)	8/114 (7.0)
2011	Bogina et al. [76]	136	IHC/SISH	All	1/136 (0.7)	0/136 (0.0)	1/136 (0.7)
2011	Chang et al. [77]	56	IHC/FISH	All	7/56 (12.5)	2/56 (3.6)	5/56 (8.9)
2010	Hoefnagel et al. [78]	233	IHC/SISH	All	12/233 (5.2)	6/233 (2.6)	6/233 (2.6)

HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; SISH, silver in situ hybridization; FISH, fluorescence in situ hybridization.

TOOLS

Similar articles